Anixa Biosciences Inc.

2.70
-0.03 (-1.10%)
At close: Apr 24, 2025, 3:59 PM
2.84
5.18%
After-hours: Apr 24, 2025, 04:41 PM EDT
-1.10%
Bid 2.68
Market Cap 86.93M
Revenue (ttm) n/a
Net Income (ttm) -12.48M
EPS (ttm) -0.39
PE Ratio (ttm) -6.92
Forward PE -7.58
Analyst Buy
Ask 2.88
Volume 29,866
Avg. Volume (20D) 82,208
Open 2.77
Previous Close 2.73
Day's Range 2.70 - 2.77
52-Week Range 2.07 - 4.20
Beta 0.52

About ANIX

Anixa Biosciences, Inc., a biotechnology company, develops therapies and vaccines focusing on critical unmet needs in oncology and infectious diseases. The company's therapeutics programs include the development of a chimeric endocrine receptor T-cell technology, a novel form of chimeric antigen receptor T-cell (CAR-T) technology focusing on the treatment of ovarian cancer; and the discovery and development of anti-viral drug candidates for the t...

Industry Biotechnology
Sector Healthcare
IPO Date Oct 7, 1983
Employees 5
Stock Exchange NASDAQ
Ticker Symbol ANIX
Full Company Profile

Analyst Forecast

According to 4 analyst ratings, the average rating for ANIX stock is "Buy." The 12-month stock price forecast is $10, which is an increase of 270.36% from the latest price.

Stock Forecasts
3 months ago
+6.05%
Anixa Biosciences shares are trading higher. D Bor... Unlock content with Pro Subscription
3 months ago
+16.6%
Anixa Biosciences shares are trading higher after the company highlighted key business milestones for 2024 and outlined goals for the next year.